The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Apellis Pharmaceuticals Inc COM 03753U106 654 29,710 SH   SOLE   29,710 0 0
Argenx COM 04016X101 28,999 346,792 SH   SOLE   346,792 0 0
Ascendis Pharma A/S COM 04351P101 33,540 504,210 SH   SOLE   504,210 0 0
Bellerophon Therapeutics COM 078771102 10,041 4,149,378 SH   SOLE   4,149,378 0 0
BioCryst Pharmaceuticals Inc COM 09058V103 14,120 2,464,241 SH   SOLE   2,464,241 0 0
Biohaven Pharmaceuticals COM G11196105 55,936 1,415,391 SH   SOLE   1,415,391 0 0
ChemoCentryx Inc COM 16383L106 304 23,064 SH   SOLE   23,064 0 0
DBV Technologies COM 23306J101 12,029 463,149 SH   SOLE   463,149 0 0
Endocyte Inc COM 29269A102 59,340 4,300,000 SH   SOLE   4,300,000 0 0
Kadmon Holdings Inc. COM 48283N106 5,632 1,411,428 SH   SOLE   1,411,428 0 0
Kiniksa Pharmaceuticals Ltd COM G5269C101 11,091 639,230 SH   SOLE   639,230 0 0
Marinus Pharmaceuticals Inc COM 56854Q101 2,441 345,240 SH   SOLE   345,240 0 0
Momenta Pharmaceuticals COM 60877T100 8,691 425,000 SH   SOLE   425,000 0 0
Obseva SA COM H5861P103 34,102 2,252,460 SH   SOLE   2,252,460 0 0
Ra Pharmaceuticals COM 74933V108 5,419 544,612 SH   SOLE   544,612 0 0
Spero Therapeutics Inc COM 84833T103 6,954 474,015 SH   SOLE   474,015 0 0
Tricida Inc COM 89610F101 28,785 962,696 SH   SOLE   962,696 0 0
Zogenix COM 98978L204 16,001 362,010 SH   SOLE   362,010 0 0